Cite
APA Citation
Duveau, N., Nachury, M., Gerard, R., Branche, J., Maunoury, V., Boualit, M., Wils, P., Desreumaux, P., & Pariente, B. (2017). adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab. Digestive and liver disease, 49(2), 163–169. http://access.bl.uk/ark:/81055/vdc_100040979327.0x00000a